Dr. Robert H. Vonderheide, Director the Abramson Cancer Center at Penn Medicine, was the keynote speaker at the 2019 Immunology & Immunotherapy for Pancreatic Cancer Symposium at Penn Medicine.
He discussed the challenges that accompany the unique pathology of pancreatic cancer.
“As pancreas cancer forms, there are multiple mechanisms of immunosuppression,” he explained.
Known as a “cold” cancer, cancer of the pancreas is notorious for its capacity to evade the immune system. Dr. Vonderheide discussed how the paradigm for immunotherapy has been modified to address pancreatic cancer’s mutational challenges.
At the Perelman School of Medicine at the University of Pennsylvania, the Vonderheide Lab focuses on scientific research and clinical investigation to advance the understanding of tumor immunology, and works to develop novel immunotherapies for cancer.
Enrolling Clinical Trials: Combination Chemotherapy/Immunotherapy for Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Dr. Vonderheide's physician profile
Advances in Immunotherapy for Pancreatic Cancer: Robert H. Vonderheide, MD, DPhil (Part 1)
Advances in Immunotherapy for Pancreatic Cancer: Robert H. Vonderheide, MD, DPhil (Part 2)